Fluid accumulation due to sickness or trauma may develop in areas within a mammalian body not designed to accommodate such accumulation. One particular area prone to abnormal accumulation is between sheets of tissue covering the outside of the lung and lining the chest cavity, known as the pleural space. While a normal functioning pleural space contains approximately 5-20 mL of fluid, fluid turnover occurs on an hourly basis such that approximately 5-10 L of fluid passes through the pleural space every day. Thus, any disruption in fluid turnover may result in over-accumulation of fluid in the pleural space, known as pleural effusion. The symptoms of pleural effusion include dyspnea, tachycardia, cough, breathing difficulty and chest pain as the lungs are prevented from fully expanding upon breathing. Pleural effusion is a condition secondary to trauma, cancer, nephrotic syndrome, kidney disease, pancreatitis, congestive heart failure and cirrhosis, and as such, patients affected with pleural effusion will usually die within three months of onset. Consequently, treatment of pleural effusion is generally provided for patient quality of life in his/her final days.
There are numerous methods to treat pleural effusion and/or other unwanted fluid accumulation in a mammalian body. Fluid drainage procedures, such as thoracentesis, may be used to provide patient relief. Thoracentesis involves the introduction of a needled catheter into the pleural space through an incision in the chest cavity, after which fluid is drawn out using a syringe or a vacuum source. Drawbacks with this procedure, however, include the fact that the needle may inadvertently puncture a lung, leading to aggravation of the problem, and the fact that fluid readily re-accumulates in the pleural space after the procedure is performed such that it may become necessary for a patient to undergo the procedure every few days. Pleurodesis is a procedure in which fluid is prevented from accumulating due to the sealing of the space between pleura with either sterile talc or an antibiotic, after first draining the existing fluid. Another method to treat pleural effusion is to surgically implant a chest tube or catheter such that fluid accumulation can constantly or periodically be removed without invasive surgery. The implanted catheter may be connected to an external catheter or drainage tube by a one-way valve mechanism, which permits fluid drainage through the use of a negative pressure source, such as a vacuum. One example of such a catheter system is described in U.S. Pat. No. 5,484,401 to Rodriguez et al., which is expressly incorporated by reference as if fully set forth herein.
While catheter-based systems have been described in the prior art, and indeed are being utilized by patients in the US, significant drawbacks exist. For example, although effective and clinically acceptable, existing catheter-based systems suffer from one or more of the following deficiencies: 1) the catheter/drainage tube connection is not secure and can be easily pulled apart (while not life threatening, accidental disconnection will cause loss of vacuum pressure mandating set-up with a new system; also, such disconnects can be the cause of pleural or peritoneal infection); 2) the clamp supplied on the drainage tube is difficult to use and is not an effective means of controlling fluid flow; 3) the system is useless in the event of an accidental loss of vacuum (effective safety mechanisms designed to prevent such accidental or premature loss of vacuum are missing); 4) the clamp sealing the vacuum chamber (which must be removed in order to activate drainage) is difficult for older patients and care givers to detach; 5) the collection chambers provided with the drainage systems (typically 500 mL) are not adequately sized for peritoneal drainage where fluid collection volumes can reach 2000 mL.
Thus, there is a need for an improved system for corporeal drainage, which will provide beneficial aspects, including those that will facilitate the use thereof regardless of patient location or condition.
Accordingly, a corporeal drainage system is described herein that provides beneficial aspects to a target user. In one aspect of the invention, a corporeal drainage system utilizes an inline pump that connects to both the implanted catheter and drainage tube via unidirectional check valves. In another aspect, an inline drip chamber is provided for a corporeal drainage system to monitoring drainage from a bodily cavity. In one embodiment, the inline pump made of a transparent material such that it serves the dual purpose of providing both an inline pump and a drip chamber.
In another aspect of the invention, a corporeal drainage system is configured for use as a passive siphoning system, in which a negative pressure is created following initial activation, in order to alleviate work required by a user in operating the system. In one embodiment, following initial activation (e.g., pump is primed, collapsible container is initially expanded from a collapsed state, etc.), the system is positioned at a level below the reservoir or cavity to be drained to create a siphon system where the weight of the fluid in the tubing acts to drag fluid out of the elevated reservoir. In another aspect of the invention, a corporeal drainage system includes a semi-reusable collection system having a multiple use outer rigid container with single use disposable inner plastic collection bag liners that has the capacity to reactivate the required vacuum for use. In still another aspect of the invention, a corporeal drainage system is configured as a single use, low cost collection system with a pre-loaded force, in which the fluid receptacle also acts as a catalyst for producing a negative pressure in the system. In one embodiment the collection system includes a bottle that is locked in a collapsed state for shipping and storing and can be activated by unlocking. In another embodiment, the collection system includes a disposable bag that can be primed or activated to produce a negative pressure, while also serving as a fluid receptacle.
In another aspect of the invention, a corporeal drainage system is provided such that an implanted catheter can be securely connected to an external fluid flow conduit with minimal effort through use of a convenient connection system. In one embodiment, the connection system includes a catheter connector that can be connected to a drainage line connector.
In one embodiment, a corporeal drainage system includes an implantable catheter, a connection tube, a connection system, including a catheter connector attached to a proximal end of the catheter and a drainage line connector attached to a distal end of the connection tube, and a pump, including a first unidirectional check valve and a second unidirectional check valve, wherein the first unidirectional check valve is positioned at one end of the pump to connect the pump to the fluid receptacle and the second unidirectional check valve is positioned at an opposite end of the pump to connect the pump to the connection tube.
In another embodiment, a corporeal drainage system includes a catheter including a catheter connector at a proximal end thereof, a connection tube including a drainage line connector at a distal end thereof, the drainage line connector and catheter connector being configured for sealing attachment to one another, and a disposable fluid receptacle in fluid communication with the connection tube, the fluid receptacle being configured to create a negative pressure within the system upon activation thereof.
A method of draining fluid from a bodily cavity using a corporeal drainage system having a fluid receptacle includes attaching a connection tube to the proximal end of an implanted catheter, initiating a negative pressure in the system such that fluid flows from the bodily cavity in a direction toward the proximal end of the catheter, and placing the fluid receptacle at a level below the bodily cavity.
These and other objectives, embodiments, features and advantages of the present invention will become more apparent to those skilled in the art when taken with reference to the following more detailed description of the invention.
The detailed description illustrates by way of example, not by way of limitation, the principles of the invention. This description will clearly enable one skilled in the art to make and use the invention, and describes several embodiments, adaptations, variations, alternatives and uses of the invention, including what is presently believed to be the best mode of carrying out the invention.
The embodiments described herein are directed to a corporeal drainage system designed to effectively provide a user the ability to drain fluid from their body in a non-clinical setting with a minimum amount of effort. The embodiments of the invention generally contain a connection tube having a proximal end that is either detachably or permanently connected to a pump or container and a distal end that is fashioned with a connector device that permits quick, easy and secure attachment to a device or mechanism inserted within a bodily cavity, including, for example, an indwelling device such as an implanted catheter or port. The connector device may be a standard luer connector or other like connectors as known to one skilled in the art. For example, if an implanted catheter has at its proximal end a female needleless injection port, the connection tube can have at its distal end a male luer connector. Particular connection systems to sealingly connect an implanted catheter to a fluid flow conduit in a corporeal drainage system are disclosed in commonly owned U.S. Provisional Application No. 60/720,443, filed Sep. 26, 2005, entitled “Catheter Connection System,” the complete contents of which are expressly incorporated by reference as if fully set forth herein.
The connection tube may be made of polyurethane or other material known to one skilled in the art suitable for a bodily fluid conduit. The connection tube should be of sufficient length to accommodate all users, such that the container may be placed on the ground or at a location beneath the cavity to be drained without undue discomfort. If the system is configured with a connection tube that is detachable from the container, different lengths can be provided by the treating clinician depending on height of the user and/or other parameters, such as likely location for the draining operation, length of the catheter extending outside of the patient's body, etc. Currently, the standard contemplated length of the connection tube is in the range of approximately 3 ft to 5 ft. The implanted catheter may be any standard medical catheter suitable for insertion into a bodily cavity, having at its proximal end a connector that attachably cooperates with the connector device attached to the connection tube (e.g., male or female luer connector). For example, suitable catheters include peritoneal catheters, thoracic drainage catheters, etc. Moreover, in the embodiments of the invention, a fluid receptacle, which may take the form, for example, of a container, disposable bottle and/or disposable bag can hold approximately 1 L of fluid, although certainly a wide range of volume capability is contemplated for the fluid receptacles of the present invention (e.g., in the range of approximately 0.5 L to 5 L).
Referring now to
The vacuum pressure provided to the system 10 is dependent on a number of factors, such as, for example, the number of times the pump 12 is activated (e.g., the number of times pressure is applied to the flexible membrane 20 and subsequently released), which can be varied based on the type of material used and the surface area of the pump 12 (rebound force of the pump (F)/surface area (A)=pressure (P)). Literature suggests that a negative pressure of approximately 30 mm Hg is the maximum that most bodily cavities in mammals are capable of withstanding. Thus, with such a relatively small amount of pressure demanded for the system, the volume of the pump and the material choice for the pump, including wall thickness and durometer, must be carefully considered so that a balance is struck between the number of pumps needed and amount of force necessary for a single activation of the pump. Such selection of wall thickness and durometer will also permit one to control the negative pressure placed into the system, which can be limited to provide a safety function (i.e., the amount of negative pressure possible can be limited by material selection such that even if the maximum amount was achieved by the user, said amount would not exceed the maximum permissible for the bodily cavity to be drained). Given the fact that system 10, and other systems described herein, will likely be used by patients with diminished strength and energy, these considerations can play an important role in the design of the system. In an exemplary embodiment, the flexible membrane 20 of pump 12 is made of 55 Shore A polyvinylchloride with a wall thickness in the range of approximately 0.05 in to approximately 0.5 in.
In order to maintain a consistent flow of fluid from the bodily cavity in prior art systems, the pump needs to be activated at least intermittently by the user. As previously mentioned, however, the target user may be unable or unwilling to do so. Thus, an advantage of the system described herein is that it is designed with the ability to act as a siphon after initial activation. Specifically, once the user has activated the pump a few times (e.g., in the system 10 described above, when the user has collapsed the flexible membrane 20 and subsequently allowed air from the system to re-expand it two or more times), the user may then place the container (e.g., container 14) on the ground (or any location below the body cavity from which drainage is taking place), which effectively creates a passive siphon system that utilizes the weight of the fluid within the catheter and/or connection tube 30 to pull fluid out of the bodily cavity (elevated reservoir). This ability to create a passive system requires only minimal effort from the user, which allows the system to be used in a non-clinical setting by a wide range of users, regardless of physical condition.
The vacuum box/container 14, while illustrated in a rectangular box form, may take on virtually any shape. The container 14 may include a lid 18 that is hinged to a body, as shown in
When the user is ready to initiate drainage of a bodily cavity, the connection tube 30 is attached to an implanted catheter via the connector 32 (e.g., luer member), or connection system as described in commonly owned U.S. Provisional Application No. 60/720,443, and the activation knob 44 is activated, unlatching the latch clasp 46 from the latch tab 48 and permitting the bottle 42 to expand, pulling fluid from the bodily cavity in the process. In order to generate sufficient force to draw the fluid out of the bodily cavity, the wall thickness of the bottle 42 must be carefully considered. In an exemplary embodiment, the bottle 42 is approximately the size of a softball, is made of an elastomeric material, and has a wall thickness in the range of approximately 0.05 in. to approximately 0.5 in. In this embodiment, the material of the bottle 42 is disposable, such that once the fluid has been extracted from the bodily cavity, the bottle 42 can be disposed of; each use requiring a new bottle. In other embodiments, the bottle 42 may include an opening such that a disposable bag or other fluid-holding container can be inserted and removed therefrom.
Through experimentation, it was noted that a pulling force of approximately 20 lbs was required to fully expand bottle 52, in order to drain fluid from a bodily cavity. Because such a force requirement may be prohibitive to some users, another method of creating a vacuum was explored. It was discovered that an initial pulling force, significantly less than the 20 lbs necessary to fully expand the bottle 52, acted to begin the fluid flow through the catheter and connection tube.
Thus, the experiment showed that a reduced pulling force, less than the force required to fully expand bottle 52, could be utilized with similar results, thereby overcoming the potential problem of requiring a user to provide a larger pulling force than could be achieved by the user. It should be noted that the amount of negative head pressure (i.e., the level or distance of a bottle or container positioned below the drainage reservoir (bodily cavity)) controls the fill rate of the bottle and amount of suction acting on the drainage catheter. Therefore, as the bottle expands and increases in weight, fluid flow rate increases. As such, in one embodiment, a bottle, such as bottle 52, is hung or otherwise suspended with a weight attached to the base thereof to increase flow rate. In another embodiment, a bottle is made of a clear material so that, in addition to the audible flow indication, a visual flow indication would be provided to the user.
The hand pumps 80 and 90 can be placed in-line into a system, connecting the connection tube 30 to either a reusable container with a disposable bag therein, a disposable bottle, or a disposable bag (e.g., zero volume collapsed bag), as described above. In one embodiment, the hand pump 90 is incorporated into system 100, as illustrated in
As discussed above, the corporeal drainage system may include a connection system for easy, fast and secure connection between an implanted catheter and a connection tube as described herein (e.g., connection tube 30). Particular connection systems for the corporeal drainage system described herein are disclosed in commonly owned U.S. Provisional Application No. 60/720,443, filed Sep. 26, 2005, entitled “Catheter Connection System,” the complete contents of which are expressly incorporated by reference as if fully set forth herein. One example of a corporeal drainage system incorporating a catheter connection system is illustrated in
In another embodiment of a corporeal drainage system, the drainage line connector 130 is attached to a connection tube, such as connection tube 30, which is connected to a fluid receptacle that also acts as a pump for the system (i.e., the initiator of negative pressure), such as illustrated in
This invention has been described and specific examples of the invention have been portrayed. While the invention has been described in terms of particular variations and illustrative figures, those of ordinary skill in the art will recognize that the invention is not limited to the variations or figures described. In addition, where methods and steps described above indicate certain events occurring in certain order, those of ordinary skill in the art will recognize that the ordering of certain steps may be modified and that such modifications are in accordance with the variations of the invention. Additionally, certain of the steps may be performed concurrently in a parallel process when possible, as well as performed sequentially as described above. Therefore, to the extent there are variations of the invention, which are within the spirit of the disclosure or equivalent to the inventions found in the claims, it is the intent that this patent will cover those variations as well. Finally, all publications and patent applications cited in this specification are herein incorporated by reference in their entirety as if each individual publication or patent application were specifically and individually put forth herein.
This application is a division of U.S. patent application Ser. No. 11/248,082, filed Oct. 12, 2005, now U.S. Pat. No. 8,337,475, which claims the benefit under 35 U.S.C. §119(e) of U.S. Provisional Application No. 60/617,758, filed Oct. 12, 2004, each of which is expressly incorporated by reference as if fully set forth herein.
Number | Name | Date | Kind |
---|---|---|---|
2547 | Welchman | Apr 1842 | A |
11623 | Waters | Aug 1854 | A |
44843 | Smith | Oct 1864 | A |
1177208 | Pierpont | Mar 1916 | A |
1197232 | Pierpont | Sep 1916 | A |
2397257 | Goland et al. | Mar 1946 | A |
3058627 | Eskridge | Oct 1962 | A |
3319684 | Calhoun | May 1967 | A |
3809087 | Lewis, Jr. | May 1974 | A |
3875941 | Adair | Apr 1975 | A |
4073294 | Stanley et al. | Feb 1978 | A |
D267433 | Pageau | Dec 1982 | S |
D267815 | Elliott et al. | Feb 1983 | S |
4429693 | Blake et al. | Feb 1984 | A |
4539985 | Magrath | Sep 1985 | A |
4583972 | Hunter et al. | Apr 1986 | A |
4642088 | Gunter | Feb 1987 | A |
4828546 | McNeil et al. | May 1989 | A |
4981474 | Bopp et al. | Jan 1991 | A |
5002528 | Palestrant | Mar 1991 | A |
5009226 | Holt | Apr 1991 | A |
5009635 | Scarberry | Apr 1991 | A |
5024653 | Kohnke | Jun 1991 | A |
5062835 | Maitz et al. | Nov 1991 | A |
5279601 | Lichte | Jan 1994 | A |
5309924 | Peabody | May 1994 | A |
5330447 | Barth | Jul 1994 | A |
5345929 | Jansson et al. | Sep 1994 | A |
5403284 | Gross | Apr 1995 | A |
5407434 | Gross | Apr 1995 | A |
5505717 | Moore | Apr 1996 | A |
5597536 | Mayer | Jan 1997 | A |
5628735 | Skow | May 1997 | A |
5637103 | Kerwin et al. | Jun 1997 | A |
D385889 | Kullas et al. | Nov 1997 | S |
5695466 | Lopez et al. | Dec 1997 | A |
5776119 | Bilbo et al. | Jul 1998 | A |
5792098 | Felix et al. | Aug 1998 | A |
5792108 | Felix et al. | Aug 1998 | A |
5807348 | Zinger et al. | Sep 1998 | A |
5810792 | Fangrow, Jr. et al. | Sep 1998 | A |
5813597 | Wakevainen | Sep 1998 | A |
5814024 | Thompson et al. | Sep 1998 | A |
5823961 | Fields et al. | Oct 1998 | A |
5830185 | Block, Jr. | Nov 1998 | A |
5839715 | Leinsing | Nov 1998 | A |
5873853 | Keilman et al. | Feb 1999 | A |
5897782 | Chatelin et al. | Apr 1999 | A |
5904334 | Grunert et al. | May 1999 | A |
5921972 | Skow | Jul 1999 | A |
5937885 | Sampson | Aug 1999 | A |
5938176 | Falconer | Aug 1999 | A |
5944703 | Dixon et al. | Aug 1999 | A |
5947953 | Ash et al. | Sep 1999 | A |
5954313 | Ryan | Sep 1999 | A |
5954706 | Sahatjian | Sep 1999 | A |
5957898 | Jepson et al. | Sep 1999 | A |
5957912 | Heitzmann | Sep 1999 | A |
5961497 | Larkin | Oct 1999 | A |
5971357 | Denton et al. | Oct 1999 | A |
5972441 | Campbell et al. | Oct 1999 | A |
5976650 | Campbell et al. | Nov 1999 | A |
5984891 | Keilman et al. | Nov 1999 | A |
5997486 | Burek et al. | Dec 1999 | A |
6001079 | Pourchez | Dec 1999 | A |
6024731 | Seddon et al. | Feb 2000 | A |
6025044 | Campbell et al. | Feb 2000 | A |
6027779 | Campbell et al. | Feb 2000 | A |
6027811 | Campbell et al. | Feb 2000 | A |
6029946 | Doyle | Feb 2000 | A |
6039302 | Cote, Sr. et al. | Mar 2000 | A |
6039714 | Cracauer et al. | Mar 2000 | A |
6056730 | Greter | May 2000 | A |
6056731 | Koetke et al. | May 2000 | A |
6063062 | Paradis | May 2000 | A |
6068011 | Paradis | May 2000 | A |
6070767 | Gardner et al. | Jun 2000 | A |
6079444 | Harris et al. | Jun 2000 | A |
6089541 | Weinheimer et al. | Jul 2000 | A |
6093154 | Burek et al. | Jul 2000 | A |
6103695 | Lane et al. | Aug 2000 | A |
6106502 | Richmond | Aug 2000 | A |
6106503 | Pfeiderer et al. | Aug 2000 | A |
6113068 | Ryan | Sep 2000 | A |
6117114 | Paradis | Sep 2000 | A |
6129699 | Haight et al. | Oct 2000 | A |
6129750 | Tockman et al. | Oct 2000 | A |
6132403 | Lopez | Oct 2000 | A |
6132407 | Genese et al. | Oct 2000 | A |
6149129 | Harris et al. | Nov 2000 | A |
6156004 | Tremaine et al. | Dec 2000 | A |
6165217 | Hayes | Dec 2000 | A |
6168137 | Paradis | Jan 2001 | B1 |
6170800 | Meloul et al. | Jan 2001 | B1 |
6171287 | Lynn et al. | Jan 2001 | B1 |
6193682 | Ahmed | Feb 2001 | B1 |
6196992 | Keilman et al. | Mar 2001 | B1 |
6200292 | French et al. | Mar 2001 | B1 |
6217556 | Ellingson et al. | Apr 2001 | B1 |
6221425 | Michal et al. | Apr 2001 | B1 |
6234992 | Haight et al. | May 2001 | B1 |
6235009 | Skow | May 2001 | B1 |
6245048 | Fangrow, Jr. et al. | Jun 2001 | B1 |
6254061 | Levine et al. | Jul 2001 | B1 |
6254581 | Scott | Jul 2001 | B1 |
6261276 | Reitsma | Jul 2001 | B1 |
6261282 | Jepson et al. | Jul 2001 | B1 |
6283949 | Roorda | Sep 2001 | B1 |
6287285 | Michal et al. | Sep 2001 | B1 |
6293929 | Smith et al. | Sep 2001 | B1 |
6299131 | Ryan | Oct 2001 | B1 |
6299593 | Wakabayashi | Oct 2001 | B1 |
6309423 | Hayes | Oct 2001 | B2 |
6328765 | Hardwick et al. | Dec 2001 | B1 |
6332892 | Desmond, III et al. | Dec 2001 | B1 |
6344033 | Jepson et al. | Feb 2002 | B1 |
6352525 | Wakabayashi | Mar 2002 | B1 |
6375024 | Park | Apr 2002 | B1 |
6391009 | Crosa Dorado et al. | May 2002 | B1 |
6409716 | Sahatjian et al. | Jun 2002 | B1 |
6428520 | Lopez et al. | Aug 2002 | B1 |
6447473 | Levine et al. | Sep 2002 | B1 |
6468190 | Fazio et al. | Oct 2002 | B1 |
6482190 | Genese et al. | Nov 2002 | B1 |
6491668 | Paradis | Dec 2002 | B1 |
6500164 | Turner et al. | Dec 2002 | B1 |
6530951 | Bates et al. | Mar 2003 | B1 |
6541116 | Michal et al. | Apr 2003 | B2 |
6551267 | Cohen et al. | Apr 2003 | B1 |
6554808 | Cook | Apr 2003 | B1 |
6562013 | Marasco, Jr. | May 2003 | B1 |
RE38145 | Lynn | Jun 2003 | E |
6620132 | Skow | Sep 2003 | B1 |
6626418 | Kiehne et al. | Sep 2003 | B2 |
6634384 | Skeens et al. | Oct 2003 | B2 |
6635020 | Tripp, Jr. et al. | Oct 2003 | B2 |
6637726 | Yamamoto | Oct 2003 | B1 |
6641562 | Peterson | Nov 2003 | B1 |
6641574 | Badia Segura et al. | Nov 2003 | B2 |
6645547 | Shekalim et al. | Nov 2003 | B1 |
6651956 | Miller | Nov 2003 | B2 |
6652484 | Hunckler et al. | Nov 2003 | B1 |
6655655 | Matkovich et al. | Dec 2003 | B1 |
6656517 | Michal et al. | Dec 2003 | B2 |
6665888 | Kwak | Dec 2003 | B1 |
6669681 | Jepson et al. | Dec 2003 | B2 |
6673049 | Hommann et al. | Jan 2004 | B2 |
6673051 | Flinchbaugh | Jan 2004 | B2 |
6695817 | Fangrow, Jr. | Feb 2004 | B1 |
6699213 | Annis et al. | Mar 2004 | B1 |
6706022 | Leinsing et al. | Mar 2004 | B1 |
6708950 | Christensen et al. | Mar 2004 | B2 |
6719991 | Darouiche et al. | Apr 2004 | B2 |
6726672 | Hanly et al. | Apr 2004 | B1 |
6730107 | Kelley et al. | May 2004 | B2 |
6733000 | McCarty et al. | May 2004 | B2 |
6733481 | Ow | May 2004 | B2 |
6745998 | Doyle | Jun 2004 | B2 |
6755391 | Newton et al. | Jun 2004 | B2 |
6780497 | Walter | Aug 2004 | B1 |
6802836 | Bouphavichith et al. | Oct 2004 | B2 |
6808161 | Hishikawa | Oct 2004 | B1 |
D500132 | Peterson et al. | Dec 2004 | S |
D500133 | Peterson et al. | Dec 2004 | S |
D500552 | Peterson et al. | Jan 2005 | S |
D500853 | Peterson et al. | Jan 2005 | S |
6840501 | Doyle | Jan 2005 | B2 |
6849061 | Wagner | Feb 2005 | B2 |
6889437 | Bader et al. | May 2005 | B2 |
6896665 | Picha et al. | May 2005 | B2 |
6897349 | Gibbins et al. | May 2005 | B2 |
6916379 | Shekalim et al. | Jul 2005 | B2 |
6936031 | Caleffi | Aug 2005 | B2 |
6972001 | Emig et al. | Dec 2005 | B2 |
6994315 | Ryan et al. | Feb 2006 | B2 |
6994325 | Riedl | Feb 2006 | B2 |
7004923 | Deniega et al. | Feb 2006 | B2 |
7004934 | Vaillancourt | Feb 2006 | B2 |
7008407 | Kamp | Mar 2006 | B1 |
7044441 | Doyle | May 2006 | B2 |
7048724 | Grossman et al. | May 2006 | B2 |
7048962 | Shekalim et al. | May 2006 | B2 |
7052603 | Schick | May 2006 | B2 |
7090191 | Matkovich et al. | Aug 2006 | B2 |
7094218 | Rome et al. | Aug 2006 | B2 |
7100890 | Cote, Sr. et al. | Sep 2006 | B2 |
7101353 | Lui et al. | Sep 2006 | B2 |
7112177 | Christensen et al. | Sep 2006 | B2 |
7147138 | Shelton, IV | Dec 2006 | B2 |
7150740 | Bennett et al. | Dec 2006 | B2 |
7163495 | Fazio et al. | Jan 2007 | B2 |
7165568 | Kessell et al. | Jan 2007 | B2 |
7179244 | Smith et al. | Feb 2007 | B2 |
7184825 | Leinsing et al. | Feb 2007 | B2 |
7207946 | Sirokman | Apr 2007 | B2 |
7303553 | Ott | Dec 2007 | B2 |
7311690 | Burnett | Dec 2007 | B2 |
7312304 | Coy et al. | Dec 2007 | B2 |
7314061 | Peppel | Jan 2008 | B2 |
7320674 | Ruddell et al. | Jan 2008 | B2 |
7341240 | Ciesielka | Mar 2008 | B2 |
7377915 | Rasmussen et al. | May 2008 | B2 |
7383073 | Abovitz et al. | Jun 2008 | B1 |
7396348 | Newton et al. | Jul 2008 | B2 |
7401703 | McMichael et al. | Jul 2008 | B2 |
7452346 | Axelsson | Nov 2008 | B2 |
7452354 | Bright et al. | Nov 2008 | B2 |
7468058 | Kanie et al. | Dec 2008 | B2 |
7497848 | Leinsing et al. | Mar 2009 | B2 |
7497849 | Fangrow, Jr. | Mar 2009 | B2 |
7524311 | Phung et al. | Apr 2009 | B2 |
7530546 | Ryan et al. | May 2009 | B2 |
7547302 | Porto et al. | Jun 2009 | B2 |
7563243 | Mendels | Jul 2009 | B2 |
7569045 | Deniega et al. | Aug 2009 | B2 |
7578803 | Rome et al. | Aug 2009 | B2 |
7584767 | Funamura et al. | Sep 2009 | B2 |
7591805 | Lampropoulos | Sep 2009 | B2 |
7594910 | Butts et al. | Sep 2009 | B2 |
7611503 | Spohn et al. | Nov 2009 | B2 |
7614123 | Schweikert | Nov 2009 | B2 |
7621903 | DeLegge | Nov 2009 | B2 |
7628774 | Fangrow, Jr. | Dec 2009 | B2 |
7628779 | Aneas | Dec 2009 | B2 |
7632260 | Antoine | Dec 2009 | B2 |
7637893 | Christensen et al. | Dec 2009 | B2 |
7644722 | Christensen et al. | Jan 2010 | B2 |
7674248 | Anderson et al. | Mar 2010 | B2 |
7678092 | Matloub et al. | Mar 2010 | B2 |
7682332 | Tanaka | Mar 2010 | B2 |
7691090 | Belley et al. | Apr 2010 | B2 |
7695458 | Belley et al. | Apr 2010 | B2 |
7708027 | Yokota et al. | May 2010 | B2 |
7717891 | Whaley | May 2010 | B1 |
7726315 | Field | Jun 2010 | B2 |
7726328 | Christensen et al. | Jun 2010 | B2 |
7736336 | Plishka et al. | Jun 2010 | B2 |
7744594 | Yamazaki et al. | Jun 2010 | B2 |
7766304 | Phillips | Aug 2010 | B2 |
7766938 | McGurk et al. | Aug 2010 | B2 |
7798974 | Sirokman | Sep 2010 | B2 |
7815168 | Vangsness et al. | Oct 2010 | B2 |
7824384 | Watson, Jr. | Nov 2010 | B2 |
7833194 | Owens et al. | Nov 2010 | B2 |
7854731 | Rome et al. | Dec 2010 | B2 |
7857284 | Kimball et al. | Dec 2010 | B2 |
7867204 | Bartholomew et al. | Jan 2011 | B2 |
7879012 | Kane et al. | Feb 2011 | B2 |
7892181 | Christensen et al. | Feb 2011 | B2 |
7924255 | Hsu et al. | Apr 2011 | B2 |
8007257 | Heaton et al. | Aug 2011 | B2 |
8048046 | Hudspeth et al. | Nov 2011 | B2 |
8048056 | Picha et al. | Nov 2011 | B2 |
8052671 | Christensen et al. | Nov 2011 | B2 |
8057448 | Williams et al. | Nov 2011 | B2 |
8074848 | Pittl et al. | Dec 2011 | B2 |
8083332 | Price et al. | Dec 2011 | B2 |
8177772 | Christensen et al. | May 2012 | B2 |
8210166 | Denton et al. | Jul 2012 | B2 |
8224422 | Mottola et al. | Jul 2012 | B2 |
8235971 | Christensen et al. | Aug 2012 | B2 |
8246590 | Hu et al. | Aug 2012 | B2 |
8337475 | Christensen et al. | Dec 2012 | B2 |
8435221 | Hu et al. | May 2013 | B2 |
8636721 | Alam et al. | Jan 2014 | B2 |
20020148467 | Bosse et al. | Oct 2002 | A1 |
20030017920 | Fazio et al. | Jan 2003 | A1 |
20030032940 | Doyle | Feb 2003 | A1 |
20030111121 | Skeens et al. | Jun 2003 | A1 |
20070100324 | Tempel et al. | May 2007 | A1 |
20070270764 | Gordon | Nov 2007 | A1 |
20070282268 | Mayse | Dec 2007 | A1 |
20090012493 | Harig | Jan 2009 | A1 |
20090069763 | DiCarlo et al. | Mar 2009 | A1 |
20090142741 | Ault et al. | Jun 2009 | A1 |
20090312725 | Braga | Dec 2009 | A1 |
20100274229 | Duocastella Codina et al. | Oct 2010 | A1 |
20110022012 | Kerr et al. | Jan 2011 | A1 |
20110071415 | Karwoski et al. | Mar 2011 | A1 |
20110105963 | Hu et al. | May 2011 | A1 |
20110172510 | Chickering, III et al. | Jul 2011 | A1 |
20110238022 | Massi et al. | Sep 2011 | A1 |
20110275964 | Greener | Nov 2011 | A1 |
20110276017 | Schuessler et al. | Nov 2011 | A1 |
Number | Date | Country |
---|---|---|
2546434 | Jan 2013 | CA |
1990003194 | Apr 1990 | WO |
1992007591 | May 1992 | WO |
1995001135 | Jan 1995 | WO |
2009027665 | Mar 2009 | WO |
2011107972 | Sep 2011 | WO |
Entry |
---|
Online dictionary entry for “tab.” Accessed Jul. 26, 2013. http://www.thefreedictionary.com/tab. |
U.S. Appl. No. 11/248,082, filed Oct. 12, 2005 Notice of Allowance dated Sep. 17, 2012. |
U.S. Appl. No. 11/248,082, filed Oct. 12, 2005 Final Office Action dated Jun. 29, 2009. |
U.S. Appl. No. 11/248,082, filed Oct. 12, 2005 Non-Final Office Action dated Dec. 21, 2010. |
U.S. Appl. No. 11/248,082, filed Oct. 12, 2005 Non-Final Office Action dated Mar. 30, 2010. |
U.S. Appl. No. 11/248,082, filed Oct. 12, 2005 Non-Final Office Action dated Oct. 30, 2008. |
U.S. Appl. No. 11/248,082, filed Oct. 12, 2005 Notice of Allowance dated Jan. 12, 2010. |
U.S. Appl. No. 11/248,082, filed Oct. 12, 2005 Notice of Allowance dated Oct. 15, 2010. |
U.S. Appl. No. 11/248,082, filed Oct. 12, 2005 Restriction Requirement dated Jan. 10, 2008. |
U.S. Appl. No. 11/535,245, filed Sep. 26, 2006 Non-Final Office Action dated Jul. 7, 2011. |
U.S. Appl. No. 11/535,245, filed Sep. 26, 2006 Final Office Action dated Mar. 17, 2011. |
U.S. Appl. No. 11/535,245, filed Sep. 26, 2006 Non-Final Office Action dated Oct. 12, 2010. |
U.S. Appl. No. 12/188,955, filed Aug. 8, 2008 Final Office Action dated Jul. 13, 2012. |
U.S. Appl. No. 12/188,955, filed Aug. 8, 2008 Non-Final Office Action dated Aug. 26, 2011. |
U.S. Appl. No. 12/188,955, filed Aug. 8, 2008 Non-Final Office Action dated Jan. 11, 2012. |
U.S. 12/879,673, filed Sep. 10, 2010 Final Office Action dated Aug. 23, 2011. |
U.S. Appl. No. 12/879,673, filed Sep. 10, 2010 Non-Final Office Action dated Feb. 1, 2011. |
U.S. Appl. No. 13/469,849, filed May 11, 2012 Non-Final Office Action dated Aug. 1, 2012. |
Vargas, F.S. et al., “Comparison of Silver Nitrate and Tetracycline as Pleural Sclerosing Agents in Rabbits.” Chest, vol. 108, No. 4, pp. 1080-1083, 1995. |
U.S. Appl. No. 10/595,450, filed Jun. 21, 2007 Non-Final Office Action dated Jun. 12, 2013. |
U.S. Appl. No. 12/188,955, filed Aug. 8, 2008 Non-Final Office Action dated Mar. 29, 2013. |
U.S. Appl. No. 13/469,849, filed May 11, 2012 Notice of Allowance dated Jun. 10, 2013. |
EP 04811627.1 filed Nov. 22, 2004 Office Action dated Feb. 11, 2014. |
U.S. Appl. No. 12/188,955, filed Aug. 8, 2008 Final Office Action dated Nov. 6, 2013. |
Number | Date | Country | |
---|---|---|---|
20130090614 A1 | Apr 2013 | US |
Number | Date | Country | |
---|---|---|---|
60617758 | Oct 2004 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11248082 | Oct 2005 | US |
Child | 13688000 | US |